The NINJA (Novel Interactor of JAZ) family is central to jasmonate (JA) signaling in plants. NINJA proteins act as transcriptional co-repressors by bridging JAZ (Jasmonate ZIM-domain) proteins to the TOPLESS (TPL) co-repressor complex, inhibiting JA-responsive genes under non-stress conditions . Key structural and functional insights include:
NINJA loss-of-function mutants (ninja) exhibit ectopic JA signaling in roots, highlighting its role in spatially restricted repression .
NINJA’s repression capacity depends on its EAR motif; mutations here abolish transcriptional inhibition .
JAZ7 and JAZ8 bypass NINJA by directly recruiting TPL via intrinsic EAR motifs .
In oncology, NINJA (iNversion INduced Joined neoAntigen) refers to a tightly regulated system for inducible neoantigen expression in mice. This system avoids thymic leakiness, preserving antigen-specific T cells for robust anti-tumor responses .
| Component | Function |
|---|---|
| FLPo recombinase | Induces DNA inversion to activate neoantigen expression |
| Doxycycline/Tamoxifen | Secondary controls for spatiotemporal induction |
| GFP reporter | Visualizes neoantigen activation |
Tumor cell lines (e.g., KP-C4A3D6) with inducible neoantigens enable studies of T cell responses .
NINJA mice show no central tolerance to induced neoantigens, unlike leaky systems (e.g., NINJA-F/C) .
AlphaScreen assays quantified NINJA-JAZ binding (IC₅₀ ≈ 0.19–0.22 μM) .
Pull-down assays using NINJA-GFP fusions confirmed interactions with JAZ3ΔC (TIFY-containing fragment) .
A commercially available antibody (Catalog # AF3485) targets Angiopoietin-like Protein 4 (ANGPTL4), a metabolic regulator .
| Parameter | Detail |
|---|---|
| Specificity | No cross-reactivity with ANGPTL3 |
| Applications | ELISA, Western blot (59 kDa band under reducing conditions) |
| Storage | -70°C long-term; avoid freeze-thaw cycles |
"Ninja-family protein 4" likely conflates:
No antibodies specifically targeting NINJA or AFP4 are documented in the provided sources. Research on these proteins relies on genetic tools (e.g., GFP fusions, mutants) rather than immunodetection .
Antibody Development: Generate antibodies against conserved NINJA/AFP domains (e.g., C-terminal region) for plant studies.
Validation: Use structural data (e.g., AlphaFold models of ZBD-TIFY interactions) to design epitopes .
Cancer Models: Expand NINJA to humanized systems for translational immuno-oncology applications .
To ensure antibody specificity, employ a multi-step validation workflow:
Western Blot with Knockout Controls: Use NINJA4 T-DNA insertion mutants (e.g., ninja4-1) as negative controls. Compare protein bands in wild-type versus mutant lysates. If the antibody recognizes a ~35 kDa band (predicted molecular weight of NINJA4) exclusively in wild-type samples, specificity is confirmed .
Immunoprecipitation (IP) Followed by Mass Spectrometry: Perform IP with the antibody on nuclear extracts from jasmonate-treated plants. Validate co-precipitated proteins via mass spectrometry; expected hits include JAZ proteins (e.g., JAZ1, JAZ3) and TOPLESS (TPL) co-repressors .
Subcellular Localization: Transfect NINJA4-GFP fusions into protoplasts and compare GFP signal localization with antibody-based immunofluorescence. Nuclear enrichment in both assays confirms targeting accuracy .
NINJA4 antibodies are critical for:
Co-Immunoprecipitation (Co-IP): Isolate NINJA4-JAZ-TPL complexes from MeJA-treated tissue. Use crosslinkers like DSP to stabilize transient interactions .
Chromatin Immunoprecipitation (ChIP): Identify NINJA4-bound promoters (e.g., MYC2 regulatory regions) under repressed jasmonate conditions. Include myc2 mutants to verify signal dependence .
Localization Studies: Track NINJA4 dynamics during stress responses. Combine antibody staining with jasmonate time-course treatments (0–12 hr) to correlate nuclear accumulation with transcriptional repression .
Perform a matrix dilution series:
Test antibody concentrations (1:50–1:1,000) against a constant protein input (1 mg lysate).
Quantify NINJA4 recovery via Western blot. Optimal dilution maximizes target signal while minimizing nonspecific bands (common at <1:200).
Include ninja4 mutant lysates to identify background noise. From , a 1:500 dilution effectively precipitates NINJA4-JAZ1 complexes without cross-reacting with AFP homologs.
Negative Controls:
Positive Controls:
Preabsorption with Recombinant NINJA4: Incubate antibody with 10x molar excess of purified NINJA4 protein (containing the C-domain epitope) for 1 hr prior to blotting. This eliminates bands matching the target’s molecular weight .
Epitope Mapping: If nonspecific bands persist, use truncated NINJA4 variants (e.g., ΔA-domain) to identify cross-reactive regions. Commercial epitope mapping services are recommended for polyclonal antibodies.
Discrepancies often arise from JAZ isoform-specific binding. Follow this workflow:
Systematic Y2H Screening: Test NINJA4 against all 12 Arabidopsis JAZ isoforms. As shown in , NINJA4 binds JAZ1, JAZ3, JAZ9, and JAZ10 but not JAZ7/JAZ8 due to TIFY motif divergence.
Quantitative Pull-Down Assays: Compare binding affinities using JAZ-MBP fusions (e.g., JAZ1ΔC vs. JAZ7ΔC). Include SPR or ITC for kinetic analysis.
Context-Dependent Analysis: Repeat assays under jasmonate-treated conditions, as hormone exposure alters JAZ stability and NINJA4 accessibility .
Phosphorylation Mapping:
Ubiquitination Assays:
Genetic Crosses: Generate NINJA4/ninja4 abi5/abi5 double mutants. Compare ABA-induced gene expression (e.g., RD29A) with single mutants.
Biochemical Competition Assays: Incubate NINJA4 with JAZ1 and ABI5 peptides. Use FRET or MST to determine binding priorities .
Phenotypic Analysis: Test root growth inhibition under ABA + MeJA co-treatment. If NINJA4 mediates cross-talk, double mutants will show additive hypersensitivity .
Tissue-Specific Knockdown: Express NINJA4 shRNAs fused to a glucocorticoid-inducible promoter. Use antibodies to monitor protein depletion in roots vs. shoots.
FRET-FLIM: Tag NINJA4 and TPL with YFP/CFP. Measure fluorescence lifetime changes in epidermal cells after MeJA treatment .
Epitope Comparison: Align NINJA4’s C-domain (residues 180–220) with AFP2/AFP3. If homology >70%, generate chimeric proteins for antibody absorption.
Selective Blocking: Preincubate antibodies with AFP2 peptide (10 µg/mL) to block cross-reactive clones without affecting NINJA4 recognition .
| JAZ Isoform | TIFY Motif Integrity | Y2H Interaction | Pull-Down Validation |
|---|---|---|---|
| JAZ1 | Intact | Yes | Yes |
| JAZ3 | Intact | Yes | Yes |
| JAZ7 | ΔTIFY (128-133) | No | No |
| JAZ10 | Intact | Yes | Yes |